Multiple Histology Phase II Trials
Authors:
Open Access
- 1 July 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (13) , 4256-4262
Abstract
Purpose: Testing agents in cancers with multiple disease subtypes, in which the activity of a new treatment may vary between subtypes, presents statistical and logistical challenges. We propose a flexible phase II strategy which includes both analyses for each histology or stratum and a combined analysis which borrows information from all the patients in the study. Sequential futility analyses are conducted once each subgroup or the overall group reaches a specified minimum accrual.Keywords
This publication has 5 references indexed in Scilit:
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II TrialsJournal of Clinical Oncology, 2008
- Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesStatistics in Medicine, 2003
- Group Sequential Designs for Monitoring Survival Probabilities1996
- Planned versus attained design in phase II clinical trialsStatistics in Medicine, 1992
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989